The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis-Reference-Cited by-同舟云学术

The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis

Published:2021-08 Issue: Volume:58 Page:50-56
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Funasaka Chikako^ORCID,Naito Yoichi^ORCID,Kusuhara Shota,Nakao Takehiro,Fukasawa Yoko,Mamishin Kanako,Komuro Ayumi,Okunaka Mashiro,Kondoh Chihiro,Harano Kenichi,Kogawa Takahiro^ORCID,Matsubara Nobuaki,Hosono Ako,Kawasaki Toshikatsu,Mukohara Toru

Funder

Meso Scale Diagnostics

Chugai Pharmaceutical

Pfizer

Sanofi

National Cancer Center

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference20 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5);Cardoso;Ann Oncol,2020

3. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline;Partridge;J Clin Oncol,2014

4. Visceral crisis means short survival among patients with luminal A metastatic breast cancer: a retrospective cohort study;Sbitti;World J Oncol,2017

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer;Miller;N Engl J Med,2007

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cisplatin Monotherapy as a Treatment Option for Patients with HER-2 Negative Breast Cancer Experiencing Hepatic Visceral Crisis or Impending Visceral Crisis;Oncology and Therapy;2024-06-04

2. Visceral crisis in metastatic breast cancer: an old concept with new perspectives;Clinics;2024-01

3. Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy;Medical Oncology;2023-12-16

4. CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis;Breast Cancer Research and Treatment;2023-08-16

5. Clinical Review on the Management of Breast Cancer Visceral Crisis;Biomedicines;2023-04-03